The global market for treatments for syndromes of dementia and movement
disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in
2012. Total market value is expected to reach $16.7 billion in 2017 after
increasing at a five-year compound annual growth rate (CAGR) of 8.5%.
The global sales of drugs to treat progressive dementia with other
neurological abnormalities expected to reach $537.2 million in 2012 and $913.7
million by 2017, at a CAGR of 11.2% over the five-year forecast period.
Sales of drugs to treat Huntington's disease patients with progressive
dementia and other neurological abnormalities expected to reach $354.4 million
in 2012 and further increase to $566.8 million in 2017, at a CAGR of 9.8% over
the five-year forecast period.
BCC's goal in conducting this study is to provide an overview of the current
and future characteristics of the global markets for treatments for syndromes
of dementia and movement disorders. The key objective is to present a
comprehensive analysis and the future direction of the market as it shapes
drug and therapy development.
This report explores present and future strategies within the
neurodegenerative disorder market, which includes treatments and therapies for
progressive dementia, progressive dementia with other neurological
abnormalities and movement disorders. Market gains, setbacks and needs are
discussed in this report. Comparisons, usage and the advantages and
disadvantages of different types of technologies, including small molecules
and monoclonal antibodies, are also presented in this report.
A detailed analysis of the structure of the syndromes of dementia and movement
disorder industry has been conducted. Revenues are broken down by
neurodegenerative disease and primary clinical/pathological feature. Sales
figures are estimated for the five-year period from 2012 through 2017.
Applications for syndromes of dementia and movement disorder treatments, or
therapeutic technologies, are also discussed separately in the report, with an
emphasis on small molecule and monoclonal antibodies technology. The report
also covers significant patents and their allotment in each category.
REASONS FOR DOING THIS STUDY
Extensive research in the field of syndromes of dementia and movement
disorders and company collaborations with research institutes have highlighted
the importance of understanding the nature of these disorders. New
technological developments are providing disease-modifying therapies for the
late stages of the disorders. Collaborations between research institutes and
pharmaceutical companies are on the rise as state-of-the-art technology is
being explored to develop more efficient products and therapies.
R&D spending, along with increasing competition, patent expiries and new
technologies are taking the market in a new direction. Global market revenues
increased from 2009 to 2011 and are expected to continue to show growth over
the forecast period as new advances, launches and collaborations continue to
influence the market. This study looks at most of the systems affected by
Acquisition strategies and collaborations by companies are also covered in
this report. This study also discusses the strength and weaknesses of each
type of technology in light of the new technologies, growing competition and
changing customer needs.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This study contributes to the areas of market growth in treatments for
Alzheimer's disease, Lewy body dementia, Pick's disease, Huntington's disease,
corticobasal ganglionic degeneration, Parkinson's disease, multiple system
atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease.
Pharmaceutical biotechnical companies, research institutes and physicians will
find this study to be of interest.
SCOPE OF THE STUDY
The scope of this study encompasses the neurodegenerative disorders in the
pharmaceutical and biotechnology markets. BCC analyzes each market and its
applications, regulatory environment, technology involved, market projections
and market share. Technological issues include the latest trends and
developments. The emerging market for enzyme inhibitors includes countries
such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New
Zealand and Mexico.
BCC conducted a comprehensive literature search, which included technical
newsletters and journals, and many other sources. Data were collected through
interviews and correspondence with manufacturers of enzyme inhibitors'
technical experts. Projections were based on estimates such as the current
number of end users, potential end users, mergers and acquisitions, and market
Many companies within the industry were surveyed to obtain data for this
study. Included were manufacturers and end users of enzyme inhibitors in
therapeutic categories and various disease sectors industries. Data were
gathered from various industry sources. BCC spoke with officials within the
industry, consulted newsletters, company literature, product literature and a
host of technical articles, journals, indexes and abstracts. Exhaustive
investigations of databases by key terminology were completed. In addition,
data were compiled from current financial, trade and government sources.
ABOUT THE AUTHOR
The study has been carried out by a team of professionals in the biotechnology
industry. The project manager for this study is Shalini S. Dewan, who holds a
master's degree in pharmaceutical chemistry and has more than 14 years of
industry experience. Among the research topics she has covered are studies on
compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl
acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India
for her work and has worked with top companies in India and in the U.S.
Some of her other reports with BCC include Reagents for Chromatography;
Spectroscopy - An Enduring Market; Advanced Drug Delivery Systems -
Technologies and Global Markets; Orthopedic Drugs, Implants and Devices -
Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory
Industry - The Dynamic Media, Sera and Reagent Market in Biotechnology;
Contract Pharmaceutical Manufacturing, Research and Packaging - Global
Markets; Chiral Technology - Global Markets; Autacoids and Related Drugs -
Technologies and Global Markets; Contraceptives - Technologies and Global
Markets; Liver Disease Treatments - The Global Market; Hormone Replacement
Therapies and Other Hormone Therapies - Global Markets; Cardiovascular
Medicine - Diagnostics, Drugs and Devices; and Cancer Therapies - Technologies
and Global Markets.
The lead consultant on this project is Ms. Ruma Chakravarty, who holds a
master's degree in biophysics. She has tremendous experience in market
research, quality, process improvement and lean and six sigma concepts.